Mesothelioma Related Clinical Trials:
Treatment of Malignant Pleural Mesothelioma With Gene Modified Cancer Cell Lines
  Â
Status: Active
Sponsors and Collaborators: Stanley S. Scott Cancer Center at Louisiana State University Medical Center - New Orleans
Information provided by: National Cancer Institute (NCI)
Government Identifier: NCT00006216
Condition: Malignant Mesothelioma
Intervention: Drug: PA-1-STK ovarian carcinoma vaccine; Drug: ganciclovir; Procedure: antiviral therapy; Procedure: recombinant viral vaccine therapy
Purpose:
RATIONALE: Ganciclovir may ease some of the side effects of cancer treatment. Vaccines made from a person's modified malignant mesothelioma cells may make the cancer more sensitive to ganciclovir.
PURPOSE: Phase I trial to study the effectiveness of vaccine therapy plus ganciclovir in treating patients who have stage I, stage II, or stage III malignant mesothelioma.
| Study Start Date: | August 1997 |
Detailed Description:
OBJECTIVES: I. Determine the safety and side effects of intrapleurally administered PA-1-STK modified ovarian carcinoma vaccine and ganciclovir in patients with stage I, II, or III malignant mesothelioma. II. Determine the maximum tolerated dose and dose limiting toxicities of this vaccine in these patients. III. Determine the immunologic response to this treatment regimen in these patients. IV. Determine the intrapleural pharmakokinetics of ganciclovir in these patients.
OUTLINE: This is a dose escalation study of PA-1-STK modified ovarian carcinoma vaccine. Patients receive PA-1-STK modified ovarian carcinoma vaccine intrapleurally on day 1 followed by ganciclovir IV over 1 hour for 7 days beginning on day 1. Patients in the first 2 cohorts receive 1 course of treatment only. In all subsequent cohorts, treatment repeats every 3 weeks for a total of 3 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3 patients receive escalating doses of PA-1-STK modified ovarian carcinoma vaccine until the maximum tolerated dose is determined.
PROJECTED ACCRUAL: A total of 3-16 patients will be accrued for this study.
Eligibility:
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
DISEASE CHARACTERISTICS: Histologically confirmed stage I, II, or III malignant mesothelioma Must have adequate pleural space in which to place chest tube or catheter
PATIENT CHARACTERISTICS: Age: Not specified Performance status: ECOG 0-1 Life expectancy: Not specified Hematopoietic: Hematocrit greater than 30% WBC greater than 4,000/mm3 Platelet count greater than 100,000/mm3 Hepatic: Bilirubin normal SGOT and alkaline phosphatase less than 1.5 times normal Renal: Creatinine less than 1.5 mg/dL Creatinine clearance greater than 50 mL/min Cardiovascular: No significant history of heart disease No frequent angina No myocardial infarction within the past 6 months No congestive heart failure requiring daily treatment Pulmonary: No evidence of moderate to severe pulmonary disease (i.e., FEV1 less than 40% predicted) Other: No prior malignancy except squamous or basal cell carcinoma of the skin No patients with childbearing potential
PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 6 weeks since prior chemotherapy Endocrine therapy: No concurrent steroid treatment Radiotherapy: At least 6 weeks since prior radiotherapy Surgery: Not specified
Contacts and Locations:
Please refer to this study by its ClinicalTrials.gov identifier: NCT00006216Locations
| United States, Louisiana | |||||
| Louisiana State University School of Medicine | |||||
| New Orleans, Louisiana, United States, 70112-2822 | |||||
Sponsors and Collaborators
| Stanley S. Scott Cancer Center at Louisiana State University Medical Center - New Orleans |
Investigators
| Study Chair: | Paul O. Schwarzenberger, MD | Stanley S. Scott Cancer Center at Louisiana State University Medical Center - New Orleans |
Additional Information:
| Study ID Numbers: | CDR0000068049, LSUMC-3591, NCI-V00-1604 |
| First Received: | September 11, 2000 |
| Last Updated: | October 25, 2007 |
| ClinicalTrials.gov Identifier: | NCT00006216 |
| Health Authority: | United States: Federal Government |
|
|
|
|
Free case consultation
If you or a loved one has been diagnosed with mesothelioma or another asbestos-related disease, contact us using the form below to speak with a mesothelioma consultant, free of charge.